Timothy H Burgess1, Clinton K Murray2, Mary F Bavaro3, Michael L Landrum4, Thomas A O'Bryan5, Jessica G Rosas6, Stephanie M Cammarata7, Nicholas J Martin8, Daniel Ewing9, Kanakatte Raviprakash10, Deepika Mor11, Elizabeth R Zell12, Kenneth J Wilkins13, Eugene V Millar14. 1. Walter Reed National Military Medical Center, 8901 Rockville Pike, Bethesda, MD 20889, USA. Electronic address: timothy.h.burgess.mil@mail.mil. 2. San Antonio Military Medical Center, 3551 Roger Brooke Drive, Fort Sam Houston, San Antonio, TX, 78234, USA. Electronic address: clinton.k.murray.mil@mail.mil. 3. Naval Medical Center, 34800 Bob Wilson Drive, San Diego, CA 92134, USA. Electronic address: mary.bavaro@med.navy.mil. 4. San Antonio Military Medical Center, 3551 Roger Brooke Drive, Fort Sam Houston, San Antonio, TX, 78234, USA; Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University, 11300 Rockville Pike, Suite 1211, Rockville, MD 20852, USA. Electronic address: michael.l.landrum@att.net. 5. San Antonio Military Medical Center, 3551 Roger Brooke Drive, Fort Sam Houston, San Antonio, TX, 78234, USA; Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University, 11300 Rockville Pike, Suite 1211, Rockville, MD 20852, USA. Electronic address: thomas.a.obryan2.ctr@mail.mil. 6. San Antonio Military Medical Center, 3551 Roger Brooke Drive, Fort Sam Houston, San Antonio, TX, 78234, USA; Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University, 11300 Rockville Pike, Suite 1211, Rockville, MD 20852, USA. Electronic address: jessica.geistman@gmail.com. 7. Naval Medical Center, 34800 Bob Wilson Drive, San Diego, CA 92134, USA; Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University, 11300 Rockville Pike, Suite 1211, Rockville, MD 20852, USA. Electronic address: stephanie.cammarata.ctr@med.navy.mil. 8. Naval Medical Research Center, 503 Robert Grant Avenue, Silver Spring, MD 20910, USA. Electronic address: nicholas.martin@fe.navy.mil. 9. Naval Medical Research Center, 503 Robert Grant Avenue, Silver Spring, MD 20910, USA. Electronic address: daniel.ewing@med.navy.mil. 10. Naval Medical Research Center, 503 Robert Grant Avenue, Silver Spring, MD 20910, USA. Electronic address: kanakatte.raviprakash@med.navy.mil. 11. Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University, 11300 Rockville Pike, Suite 1211, Rockville, MD 20852, USA. Electronic address: dmor@idcrp.org. 12. Stat-Epi Associates Inc., 13 Sea Winds Lane South, Ponte Vedra Beach, FL 32082, USA. Electronic address: erzell@stat-epi.com. 13. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA. Electronic address: kenneth.wilkins@nih.gov. 14. Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University, 11300 Rockville Pike, Suite 1211, Rockville, MD 20852, USA. Electronic address: emillar@idcrp.org.
Abstract
BACKGROUND: In outbreak settings, mass vaccination strategies could maximize health protection of military personnel. Self-administration of live attenuated influenza vaccine (LAIV) may be a means to vaccinate large numbers of people and achieve deployment readiness while sparing the use of human resources. METHODS: A phase IV, open-label, randomized controlled trial evaluating the immunogenicity and acceptance of self-administered (SA) LAIV was conducted from 2012 to 2014. SA subjects were randomized to either individual self-administration or self-administration in a group setting. Control randomized subjects received healthcare worker-administered (HCWA) LAIV. Anti-hemagglutinin (HAI) antibody concentrations were measured pre- and post-vaccination. The primary endpoint was immunogenicity non-inferiority between SA and HCWA groups. Subjects were surveyed on preferred administration method. RESULTS: A total of 1077 subjects consented and were randomized (529 SA, 548 HCWA). Subject characteristics were very similar between groups, though SA subjects were younger, more likely to be white and on active duty. The per-protocol analysis included 1024 subjects (501 SA, 523 HCWA). Post-vaccination geometric mean titers by vaccine strain and by study group (HCWA vs. SA) were: A/H1N1 (45.8 vs. 48.7, respectively; p=0.43), A/H3N2 (45.5 vs. 46.4; p=0.80), B/Yamagata (17.2 vs. 17.8; p=0.55). Seroresponses to A components were high (∼67%), while seroresponses to B components were lower (∼25%). Seroresponse did not differ by administration method. Baseline preference for administration method was similar between groups, with the majority in each group expressing no preference. At follow-up, the majority (64%) of SA subjects preferred SA vaccine. CONCLUSIONS:LAIV immunogenicity was similar for HCWA and SA vaccines. SA was well-tolerated and preferred to HCWA among those who performed SA.
RCT Entities:
BACKGROUND: In outbreak settings, mass vaccination strategies could maximize health protection of military personnel. Self-administration of live attenuated influenza vaccine (LAIV) may be a means to vaccinate large numbers of people and achieve deployment readiness while sparing the use of human resources. METHODS: A phase IV, open-label, randomized controlled trial evaluating the immunogenicity and acceptance of self-administered (SA) LAIV was conducted from 2012 to 2014. SA subjects were randomized to either individual self-administration or self-administration in a group setting. Control randomized subjects received healthcare worker-administered (HCWA) LAIV. Anti-hemagglutinin (HAI) antibody concentrations were measured pre- and post-vaccination. The primary endpoint was immunogenicity non-inferiority between SA and HCWA groups. Subjects were surveyed on preferred administration method. RESULTS: A total of 1077 subjects consented and were randomized (529 SA, 548 HCWA). Subject characteristics were very similar between groups, though SA subjects were younger, more likely to be white and on active duty. The per-protocol analysis included 1024 subjects (501 SA, 523 HCWA). Post-vaccination geometric mean titers by vaccine strain and by study group (HCWA vs. SA) were: A/H1N1 (45.8 vs. 48.7, respectively; p=0.43), A/H3N2 (45.5 vs. 46.4; p=0.80), B/Yamagata (17.2 vs. 17.8; p=0.55). Seroresponses to A components were high (∼67%), while seroresponses to B components were lower (∼25%). Seroresponse did not differ by administration method. Baseline preference for administration method was similar between groups, with the majority in each group expressing no preference. At follow-up, the majority (64%) of SA subjects preferred SA vaccine. CONCLUSIONS: LAIV immunogenicity was similar for HCWA and SA vaccines. SA was well-tolerated and preferred to HCWA among those who performed SA.
Authors: Christopher J Phillips; Tabitha Woolpert; Carter Sevick; Dennis Faix; Patrick J Blair; Nancy F Crum-Cianflone Journal: Clin Infect Dis Date: 2012-11-26 Impact factor: 9.079
Authors: Matt Zahn; Priscilla Pursiful; Ruth Carrico; Charles Woods; Adewale Troutman Journal: Disaster Med Public Health Prep Date: 2013-04 Impact factor: 1.385
Authors: T Rowe; R A Abernathy; J Hu-Primmer; W W Thompson; X Lu; W Lim; K Fukuda; N J Cox; J M Katz Journal: J Clin Microbiol Date: 1999-04 Impact factor: 5.948
Authors: Brenda L Coleman; Allison J McGeer; Scott A Halperin; Joanne M Langley; Yassein Shamout; Anna Taddio; Vibhuti Shah; Shelly A McNeil Journal: Vaccine Date: 2012-08-16 Impact factor: 3.641
Authors: Mark S Riddle; David R Tribble; Shannon D Putnam; Manal Mostafa; Theodore R Brown; Andrew Letizia; Adam W Armstrong; John W Sanders Journal: Am J Public Health Date: 2008-10-15 Impact factor: 9.308
Authors: Nadine G Rouphael; Michele Paine; Regina Mosley; Sebastien Henry; Devin V McAllister; Haripriya Kalluri; Winston Pewin; Paula M Frew; Tianwei Yu; Natalie J Thornburg; Sarah Kabbani; Lilin Lai; Elena V Vassilieva; Ioanna Skountzou; Richard W Compans; Mark J Mulligan; Mark R Prausnitz Journal: Lancet Date: 2017-06-27 Impact factor: 79.321
Authors: Brandi T Johnson-Weaver; Hae Woong Choi; Hang Yang; Josh A Granek; Cliburn Chan; Soman N Abraham; Herman F Staats Journal: Front Immunol Date: 2021-09-10 Impact factor: 7.561